Boston Scientific (Boston Scientific) Total Liabilities : $15,606.00 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Boston Scientific Total Liabilities?

Boston Scientific's Total Liabilities for the quarter that ended in Dec. 2023 was $15,606.00 Mil.

Boston Scientific's quarterly Total Liabilities declined from Jun. 2023 ($15,116.00 Mil) to Sep. 2023 ($14,914.00 Mil) but then increased from Sep. 2023 ($14,914.00 Mil) to Dec. 2023 ($15,606.00 Mil).

Boston Scientific's annual Total Liabilities declined from Dec. 2021 ($15,607.00 Mil) to Dec. 2022 ($14,896.00 Mil) but then increased from Dec. 2022 ($14,896.00 Mil) to Dec. 2023 ($15,606.00 Mil).

Boston Scientific Total Liabilities Historical Data

The historical data trend for Boston Scientific's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boston Scientific Total Liabilities Chart

Boston Scientific Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

16,688.00

15,451.00

15,607.00

14,896.00

15,606.00

Boston Scientific Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															14,783.00	15,116.00	14,914.00	15,606.00	-

Boston Scientific Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Boston Scientific's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4933	+	(8961	+	1267
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	445	+	0)
	=	15,606.00

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	35136	-	19530
	=	15,606.00

Boston Scientific's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4933	+	(8961	+	1267
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	445	+	0)
	=	15,606.00

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	35136	-	19530
	=	15,606.00

Boston Scientific Total Liabilities Related Terms

Thank you for viewing the detailed overview of Boston Scientific's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Boston Scientific (Boston Scientific) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Boston Scientific Corp (NYSE:BSXpA.PFD) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

BSX:USA BSX:Mexico 1BSX:Italy BSX:Germany BSX:Germany BSX:Germany B1SX34:Brazil BSXC:Austria

Address

300 Boston Scientific Way, Marlborough, MA, USA, 01752-1234

Website

https://www.bostonscientific.com

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.